Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Link Technologies Announces Expansion into the Far East with New Distributor

Published: Thursday, June 13, 2013
Last Updated: Thursday, June 13, 2013
Bookmark and Share
Zirench Technology signed as local distributor for the Chinese market.

Link Technologies Ltd has announced Zirench Technology Co. Ltd as distributor in China, the first Asian distributor for its comprehensive range of products.

Located in Dalian City, Zirench Technology will represent Link Technologies in China, expanding their reach across the country and providing invaluable local support for customers.

The appointment of Zirench Technology is the first signing of multiple, upcoming distributorship agreements in the Far East, and is testament to Link Technologies’ on-going strategic development and growth.

As an ISO 9001:2008 certified supplier of products for oligonucleotide synthesis, Link Technologies is committed to providing all customers with high purity, reliable oligo precursors and reagents, which can now extend to customers in China, thanks to Zirench Technology.

Commenting on the new distributor agreement, Dr John Bremner, CEO at Link Technologies, said: “We are working hard to effectively deliver our products to customers in research and industrial institutions in Asia and other parts of the world, where easily accessible local support and expertise is very important. We are delighted that this deal with Zirench boosts this strategy.”

Dr Victor Liu, Commercial Manager at Zirench Technology, added “Our aim is to offer our customers laboratory instruments, supplies and biological agents of world-class quality. As such, we were keen to act on behalf of Link Technologies, to raise awareness of and distribute their high quality oligo precursor products across China.”

Providing a broad catalogue of reagents for DNA, RNA and PNA synthesis, Link Technologies has particular expertise in the manufacture of modified nucleic acid products, often unavailable elsewhere.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Link Technologies Inks Exclusive License to Agilent Technologies’ TC RNA Monomers
Under the terms of the agreement Link will manufacture and sell the four RNA monomer phosphoramidite reagents for use in research.
Monday, May 18, 2009
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Symmetry is Key to Collagen
Researchers describe how symmetry may be the key to growing collagen fibres outside the body.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!